Discovering & Developing the Next Generation Therapies.
Innovimmune Biotherapeutics is a specialty biopharmaceutical company focused on the Drug Discovery and Exploratory Development of the next generation immunomodulatory drugs within the core disease therapeutic areas of Autoimmune & Inflammatory Diseases.
Core Value Proposition.
At Innovimmune, we are working to discover and develop proprietary low-risk, first-in-class, best-in-class oral small molecule NMEs from Lead Development to Preclinical and Clinical Proof of Concept stages, which selectively target MOAs of a common pathogenetic pathway of several Autoimmune & Inflammatory Disease indications with high unmet medical needs.
Industry-Leading Drug Developers.
We have assembled a world-class management and scientific team of industry Research and Development leaders from Roche, Pfizer, Merck, Schering-Plough & AstraZeneca, as well as, those from Academia. The Innovimmune team has a successful Discovery, Development and Commercialization track-record of advancing >80 NMEs across all drug development lifecycles, >90 worldwide patent filings and >270 peer-reviewed scientific publications (including Science and Nature) mostly within the Autoimmune and ImmunoInflammation Disease therapeutic areas. Our experienced Discovery and Development experts from the pharmaceutical and biotechnology industries represent the best of their individual fields in Translational Medicine, Clinical Development, Computational Chemistry, Medicinal Chemistry, Biochemistry, Biophysics, Enzymology, Drug Metabolism & Pharmacokinetics, Molecular Biology, Cell Biology, Immunology, Pharmacology, Pathology and Biochemistry. We are industry experts in the fields of Autoimmunity, Inflammation, Cytokine, Chemokine, Nuclear Hormone Receptors, GPCRs, Signal Transduction and Kinase Biology with the unique credentials to innovate the drug discovery and exploratory development of novel NME targets for Autoimmune and ImmunoInflammatory diseases.